X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
inotuzumab ozogamicin (220) 220
index medicus (191) 191
humans (143) 143
oncology (121) 121
hematology (99) 99
acute lymphoblastic leukemia (86) 86
chemotherapy (74) 74
cancer (69) 69
minimal residual disease (61) 61
gemtuzumab ozogamicin (60) 60
blinatumomab (58) 58
leukemia (53) 53
monoclonal antibodies (53) 53
antineoplastic agents - therapeutic use (52) 52
acute lymphocytic leukemia (49) 49
immunotherapy (49) 49
acute lymphocytic-leukemia (47) 47
animals (47) 47
pharmacology & pharmacy (46) 46
adult (44) 44
acute lymphoblastic-leukemia (43) 43
antibodies, monoclonal - therapeutic use (42) 42
acute myeloid-leukemia (41) 41
hyper-cvad (41) 41
adult patients (40) 40
rituximab (39) 39
care and treatment (37) 37
immunoconjugates - therapeutic use (35) 35
monoclonal-antibody (35) 35
phase-ii (35) 35
female (34) 34
therapy (34) 34
brentuximab vedotin (32) 32
phase-i (32) 32
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (31) 31
male (29) 29
precursor cell lymphoblastic leukemia-lymphoma - therapy (29) 29
stem-cell transplantation (29) 29
term-follow-up (29) 29
transplantation (28) 28
antibodies (27) 27
calicheamicin (27) 27
cd22 (27) 27
medicine & public health (27) 27
adults (26) 26
lymphomas (26) 26
acute lymphatic leukemia (25) 25
drug therapy (25) 25
lymphatic leukemia (25) 25
non-hodgkins-lymphoma (25) 25
aged (24) 24
antibodies, monoclonal, humanized - therapeutic use (24) 24
t cells (24) 24
treatment outcome (24) 24
antibody-drug conjugate (23) 23
antibody-drug conjugates (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
immunoconjugate (23) 23
inotuzumab (23) 23
middle aged (23) 23
article (22) 22
biopharmaceutics (22) 22
chronic lymphocytic-leukemia (22) 22
health aspects (22) 22
molecular targeted therapy (22) 22
prognosis (22) 22
t-cells (22) 22
clinical activity (21) 21
hemic and lymphatic diseases (21) 21
neoplasms - drug therapy (21) 21
review (21) 21
antigens (20) 20
clinical trials as topic (20) 20
immunology (20) 20
recurrence (20) 20
research (20) 20
stem cells (20) 20
antineoplastic agents (19) 19
clinical trials (19) 19
non-hodgkin-lymphoma (19) 19
antibody-targeted chemotherapy (18) 18
cytotoxicity (18) 18
patients (18) 18
precursor cell lymphoblastic leukemia-lymphoma - pathology (18) 18
relapse (18) 18
adolescent (17) 17
antimitotic agents (17) 17
antitumor-activity (17) 17
brentuximab vedotin sgn-35 (17) 17
elderly-patients (17) 17
immunotherapy - methods (17) 17
lymphoma (17) 17
medical research (17) 17
medicine, research & experimental (17) 17
monoclonal antibody (17) 17
remission (17) 17
lymphocytes b (16) 16
phase-ii trial (16) 16
remission induction (16) 16
stem cell transplantation (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 08/2013, Volume 119, Issue 15, pp. 2728 - 2736
Journal Article
European Journal of Haematology, ISSN 0902-4441, 05/2017, Volume 98, Issue 5, pp. 425 - 434
Despite an improved understanding of disease biology and the use of multi‐agent chemotherapy, the long‐term survival of adults with B‐cell acute lymphoblastic... 
relapsed acute lymphoblastic leukemia | inotuzumab ozogamicin | GEMTUZUMAB OZOGAMICIN | CD22 MONOCLONAL-ANTIBODY | ANTIBODY-TARGETED CHEMOTHERAPY | PROGNOSTIC-FACTORS | ACUTE LYMPHOCYTIC-LEUKEMIA | CD22-TARGETED IMMUNOCONJUGATE | NON-HODGKIN-LYMPHOMA | SALVAGE THERAPY | HEMATOLOGY | CLINICAL ACTIVITY | PHASE-I | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - epidemiology | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Prognosis | Humans | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Combined Modality Therapy | Molecular Targeted Therapy | Lymphoma, Non-Hodgkin - pathology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antibodies, Monoclonal, Humanized - pharmacology | Antineoplastic Agents - pharmacology | Drug Evaluation, Preclinical | Lymphoma, Non-Hodgkin - drug therapy | CD22 antigen | Endocytosis | Chemotherapy | Acute lymphatic leukemia | Cell survival | Immunoconjugates | Lymphocytes B | Leukemia | Lymphatic leukemia
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 2018, Volume 12, pp. 2293 - 2300
Despite improved rates of remission and cure in newly diagnosed adult acute lymphoblastic leukemia (ALL), the prognosis for patients with relapsed or... 
Inotuzumab ozogamicin | Acute lymphoblastic leukemia | Relapsed/refractory | CD22 | Monoclonal antibody-Drug conjugate | MULTIORGAN FAILURE | CHEMISTRY, MEDICINAL | ANTIBODY-TARGETED CHEMOTHERAPY | VENOOCCLUSIVE DISEASE | BONE-MARROW-TRANSPLANTATION | ACUTE LYMPHOCYTIC-LEUKEMIA | inotuzumab ozogamicin | INO-VATE | acute lymphoblastic leukemia | mono-clonal antibody-drug conjugate | relapsed/refractory | NON-HODGKIN-LYMPHOMA | PHARMACOLOGY & PHARMACY | MONOCLONAL-ANTIBODIES | PHASE-I | CLINICAL ACTIVITY | Anti-Bacterial Agents - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Adult | Antineoplastic Agents - therapeutic use | Aminoglycosides - therapeutic use | Antigens | Medical research | Prognosis | Ofatumumab | B cells | Vincristine | Drug approval | Biopharmaceutics | Chemotherapy | Immunotherapy | Medicine, Experimental | Acute lymphocytic leukemia | Cancer | Calicheamicin | Acute lymphatic leukemia | Toxicity | Leukemia | Clinical trials | Cytotoxicity | Lymphatic leukemia | Patients | Survival | CD22 antigen | Antibiotics | Lymphocytes B | Medical prognosis | Monoclonal antibodies | Remission | Blast cells | Pediatrics | Transplants & implants | Cancer therapies | Cell adhesion & migration | Signal transduction | Cell cycle | Bone marrow | Drug dosages | Immunoglobulins | Medicine | Studies | Refractory materials | Stem cells | Lymphomas | Adults | Apoptosis | monoclonal antibody drug conjugate
Journal Article
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2151 - 2160
BACKGROUND Inotuzumab ozogamicin (InO), an anti‐CD22 antibody‐calicheamicin conjugate, demonstrated superior clinical activity versus standard‐of‐care (SOC)... 
clinical study | quality of life | acute lymphoblastic leukemia | inotuzumab ozogamicin | patient‐reported outcomes | patient-reported outcomes | SURVIVAL | ADULT PATIENTS | RELAPSE | IMPACT | ONCOLOGY | CLINICAL-TRIALS | QUALITY-OF-LIFE | BLINATUMOMAB | MONOCLONAL-ANTIBODIES | Dyspnea - chemically induced | Antibodies, Monoclonal, Humanized - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Male | Fatigue - chemically induced | Neoplasm Recurrence, Local - mortality | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dyspnea - epidemiology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Fatigue - epidemiology | Sialic Acid Binding Ig-like Lectin 2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Quality of Life | Female | Precursor Cell Lymphoblastic Leukemia-Lymphoma - microbiology | Health Status | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Patient Reported Outcome Measures | Care and treatment | Analysis | Clinical trials | Outcome and process assessment (Health Care) | Acute lymphocytic leukemia | Research | Quality of life | Appetite | Calicheamicin | Statistical analysis | Acute lymphatic leukemia | Leukemia | Fatigue | Lymphatic leukemia | Patients | Confidence intervals | CD22 antigen | Randomization | Cytarabine | Dyspnea | Fludarabine | Lymphocytes B | Respiration | Mitoxantrone | Leukocytes (granulocytic) | Constipation | Public health | Cancer
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 03/2019, Volume 85, Issue 3, pp. 590 - 600
Aim The aim of this study was to characterize the effect of inotuzumab ozogamicin on QT interval in patients with B‐cell malignancies. Methods Data were pooled... 
QT interval | B‐cell non‐Hodgkin lymphoma | B‐cell acute lymphoblastic leukaemia | inotuzumab ozogamicin | population pharmacokinetics | B-cell non-Hodgkin lymphoma | B-cell acute lymphoblastic leukaemia | THERAPY | RITUXIMAB | ACUTE LYMPHOBLASTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | IMMUNOCONJUGATE
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2016, Volume 174, Issue 4, pp. 571 - 581
Journal Article
Journal Article